Biotechnology

As Orca Bio builds a manufacturing empire from Sacramento to Princeton, it's not just preparing for a new drug launch—it's trying to solve the biggest puzzle in biotech.

A US food-tech innovator and a Bulgarian industrial giant are quadrupling animal-free egg protein production, signaling a tectonic shift in global supply chains.

Sumitomo Pharma's new data reveals a potent combination therapy for myelofibrosis and decodes resistance in leukemia, shaking up a competitive oncology landscape.

A new precision drug, ART5803, is offering hope for a devastating brain disorder. Arialys Therapeutics is fast-tracking its development with key clinical trials.

With a $50M seed round, Radical Numerics aims to build general biological intelligence, walking a fine line between curing disease and creating bioweapons.

A new study offers hope for MS by promoting nerve repair, but the real story is the validation of a versatile stem cell platform for a new era of medicine.

New data reveals elevated cortisol in over 75% of hard-to-treat diabetes patients, paving the way for a novel drug to tackle treatment resistance.

Facing a 'going concern' warning and collapsing revenue, Splash Beverage Group is ditching drinks for drugs. Its investment in Avicanna is a desperate, yet strategic, pivot.

Fate Therapeutics' new board appointment signals a major shift. Can a commercial veteran turn groundbreaking iPSC science into accessible, off-the-shelf medicine?

For decades, patients with advanced chondrosarcoma had no options. Now, a new drug's journey to the FDA offers a lifeline and a lesson in medical neglect.

A single AML patient's journey to a stem cell transplant after treatment with CER-1236 offers a glimmer of hope, but is it a breakthrough or a mirage?

While CEO Craig Chambliss's EY award makes headlines, the real story is Neurelis's disruption of epilepsy care and its ambitious pipeline for brain disorders.

Legend Biotech's stunning trial results for an 'in vivo' CAR-T therapy could make advanced cancer treatment faster, safer, and accessible to all.

Phase 1 data for Marea Therapeutics’ MAR002 suggests a potential new era for acromegaly treatment, promising better control with far fewer injections.

Biocytogen's new 'gold standard' accreditation isn't just about animal welfare. It's a calculated move to de-risk drug development and win global partners.

With a landmark therapy for Sanfilippo Syndrome nearing the FDA, Spruce adds veteran marketing and finance chiefs. A look at the talent behind the transition.

A new, single-shot vaccine for dogs targets two spreading diseases. This innovation aims to make vet visits less stressful and close critical health gaps.

Elysium Health's new Creatine+ isn't just a supplement; it's a signal of a massive structural shift where human vitality becomes a core economic asset.

Alexandria Real Estate's top WSJ ranking for talent readiness reveals a new playbook where human capital is the most valuable asset, even in real estate.

A world-first treatment in Canada saved a young burn victim's face, bypassing devastating grafts. But can this 'miracle' therapy move from one-off to standard care?